Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第9页

Evaluating the accuracy of extrapolated overall survival for pembrolizumab: a comparison with long-term observed data in the Australian reimbursement context. 澳大利亚报销当局评估派姆单抗的长期总生存期与外推总生存期的比较

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-04-04 DOI: 10.1080/14737167.2025.2478234

Francis C Dehle, Kevin Phan, Jerome Higgins, Kate Applegarth, Manoj Gambhir, Colman B Taylor

{"title":"Evaluating the accuracy of extrapolated overall survival for pembrolizumab: a comparison with long-term observed data in the Australian reimbursement context.","authors":"Francis C Dehle, Kevin Phan, Jerome Higgins, Kate Applegarth, Manoj Gambhir, Colman B Taylor","doi":"10.1080/14737167.2025.2478234","DOIUrl":"10.1080/14737167.2025.2478234","url":null,"abstract":"Background: Decisions about government funding for new medicines often rely on statistical models to predict how long patients will live (overall survival, OS) based on early trial data. This study compared the accuracy of these predictions for the cancer drug pembrolizumab, using models preferred by pharmaceutical companies (Sponsors) and the Pharmaceutical Benefits Advisory Committee (PBAC), compared to real-world long-term follow-up (LTFU) data.Research design and methods: We reviewed publicly available PBAC summary documents (PSDs) for all funding decisions on pembrolizumab up to November 2022. We included cases with at least three years of follow-up data and where at least 350 patients per year would be treated. We then compared survival predictions from PBAC and Sponsor models to actual survival data at two time points.Results: A total over 38 PSDs covering 15 indications, five met our criteria. Sponsor-preferred models underestimated real survival by 0.54% to 16.45%, while PBAC-preferred models underestimated survival by 1.20% to 24.21%.Conclusion: Results demonstrate that OS extrapolation methods used by both the Sponsor and PBAC tend to underestimate long-term survival outcomes for pembrolizumab indications, with PBAC-preferred methods being more conservative.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"743-750"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Indication-based pricing of the pharmaceuticals in Croatia: case-study. 克罗地亚基于适应症的药品定价：案例研究。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-14 DOI: 10.1080/14737167.2025.2478232

Ana Bobinac, Luka Vončina, Ismar Velić, Elizabeta Ribarić, Vanesa Benković

{"title":"Indication-based pricing of the pharmaceuticals in Croatia: case-study.","authors":"Ana Bobinac, Luka Vončina, Ismar Velić, Elizabeta Ribarić, Vanesa Benković","doi":"10.1080/14737167.2025.2478232","DOIUrl":"10.1080/14737167.2025.2478232","url":null,"abstract":"Background: Rising pharmaceutical expenditure worldwide, including in Croatia, is putting considerable pressure on healthcare budgets. Oncology drugs, often used in several indications with varying efficacy, contribute to this challenge, and a single price is paid regardless of the indication. This study investigates whether indication-based pricing (IBP), a method of pricing the same drug for different indications based on its relative value in different treatment applications, could be a potential solution to contain drug expenditure.Research design and methods: We operationalized IBP in two ways: by anchoring all drug prices according to the indication that provides the most or least benefit, and second, by anchoring drug prices to a cost-effectiveness threshold estimated for Croatia. We also interviewed policymakers in Croatia to determine whether they are familiar with the problem of differential effectiveness of medicines with multiple indications.Results: Applying IBP to the oncology drug abiraterone in three indications, as measured by life-years gained (LYGs) and quality-adjusted life-years (QALYs), shows the effectiveness of abiraterone varies considerably by indication. Depending on the IBP approach chosen, drug prices can be reduced by 74% or increased by up to 280%.Conclusions: Drug prices can vary dramatically depending on the IBP approach chosen.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"761-768"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis. 帕金森病患者步态冻结结果测量的心理测量特性：系统回顾和荟萃分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-13 DOI: 10.1080/14737167.2025.2477473

Prisca Proietti, Ilaria Ruotolo, Alessandra Carlizza, Alessandro Ugolini, Giovanni Galeoto, Giovanni Fabbrini, Giovanni Sellitto

{"title":"Psychometric properties of outcome measures for freezing of gait in Parkinson's disease: a systematic review and meta-analysis.","authors":"Prisca Proietti, Ilaria Ruotolo, Alessandra Carlizza, Alessandro Ugolini, Giovanni Galeoto, Giovanni Fabbrini, Giovanni Sellitto","doi":"10.1080/14737167.2025.2477473","DOIUrl":"10.1080/14737167.2025.2477473","url":null,"abstract":"Introduction: This systematic review and meta-analysis evaluated validated tools for assessing FOG in PD, focusing on their psychometric properties, linguistic adaptations, and methodological quality.Methods: A systematic search was conducted in MEDLINE, CINAHL, SCOPUS, and Web of Science, following PRISMA-COSMIN guidelines. Studies assessing validity, reliability, and cross-cultural adaptation of FOG-specific tools were included. Key psychometric properties, such as internal consistency (Cronbach's alpha) and test-retest reliability (Intraclass Correlation Coefficient, ICC), were extracted. The COSMIN Risk of Bias checklist was used to assess methodological quality, and meta-analyses were performed for comparable studies.Results: Six validated tools were identified, with FOG-Q and NFOG-Q emerging as the most robust. Meta-analysis showed high internal consistency (FOG-Q: α = 0.90; NFOG-Q: α = 0.87-0.89) and test-retest reliability (FOG-Q ICC = 0.87), though substantial heterogeneity was noted (I² = 71.1-86.4%). Emerging tools, including CFOG-Q, Ziegler test, and DYPAGS, addressed cognitive and dual-tasking aspects but lacked linguistic validation.Conclusion: FOG-Q and NFOG-Q remain widely used, yet NFOG-Q may have limitations in detecting small clinical changes. Broader linguistic adaptations are needed, and emerging tools hold promise for multidimensional assessment. Future research should integrate subjective and objective measures for comprehensive evaluations.Registration: PROSPERO (CRD42020173873).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"647-659"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China. 匹配校正的间接比较和成本-效果盐酸米托蒽醌脂质体与奇达胺治疗复发或难治性外周t细胞淋巴瘤。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-25 DOI: 10.1080/14737167.2025.2482667

Ying Liu, Xiaoning He

{"title":"Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China.","authors":"Ying Liu, Xiaoning He","doi":"10.1080/14737167.2025.2482667","DOIUrl":"10.1080/14737167.2025.2482667","url":null,"abstract":"Background: Mitoxantrone hydrochloride liposome (PLM60) is a novel liposome formulation, approved in China for the treatment of patients diagnosed with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This study aimed to assess the cost-effectiveness of PLM60 versus chidamide (CS055) in R/R PTCL from the Chinese healthcare perspective.Research design and methods: We conducted a cost-utility analysis using a partitioned survival model with a 5-year horizon, applying a 5% discount rate to both costs and health outcomes. Owing to the lack of head-to-head comparison between the two drugs, we employed an unanchored matching-adjusted indirect comparison (MAIC) to estimate relative efficacy and safety outcomes. Utility values and costs were obtained from published literature and clinical expert consultations. Sensitivity analyses were performed to evaluate the robustness of results.Results: In the base case analysis, PLM60 saved Chinese Yuan 77,397 (226,075 vs. 303,472) and gained an additional 0.10 (1.30 vs. 1.20) quality-adjusted life years compared to CS055, making it the strongly dominant treatment option. Comprehensive sensitivity analyses confirmed the robustness of the results.Conclusion: PLM60 was estimated to be a cost-effective treatment for R/R PTCL compared with CS055 from a Chinese healthcare perspective, which provided patients with an effective and cost-saving treatment option.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"795-804"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China. trilaciclib在中国广泛期小细胞肺癌患者中降低化疗诱导骨髓抑制发生率的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-12 DOI: 10.1080/14737167.2025.2478241

Nan Fang, Xuan Xia, Xiaoning He

{"title":"Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China.","authors":"Nan Fang, Xuan Xia, Xiaoning He","doi":"10.1080/14737167.2025.2478241","DOIUrl":"10.1080/14737167.2025.2478241","url":null,"abstract":"Background: Chemotherapy-induced myelosuppression (CIM) is the most common adverse event associated with chemotherapy. The recently approved novel pharmacotherapy trilaciclib demonstrates potential to provide multilineage protection against CIM. This study aimed to evaluate the cost-effectiveness of trilaciclib among patients with extensive-stage small cell lung cancer (ES-SCLC) in China.Research design and methods: A short-term Markov model and long-term partitioned survival model were developed to simulate disease progression during and after chemotherapy over a lifetime horizon. Clinical, cost, and utility parameters were obtained from three pivotal clinical trials of trilaciclib, published literature, and expert opinion. Total cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated. Scenario analyses and sensitivity analyses assessed model robustness.Results: The lifetime incremental cost per patient for trilaciclib was CN¥22,828 (US$3,210), with an incremental QALY of 0.093, yielding an ICER of CN¥245,841 (US$34,565) per QALY gained. This ICER falls below China's willingness-to-pay threshold of three times per-capita GDP (CN¥268,074, US$37,691). Extensive sensitivity analyses confirmed the robustness of the base-case findings.Conclusions: Trilaciclib represents a cost-effective option for reducing the incidence of CIM in ES-SCLC patients. These results support reimbursement decisions and pricing strategies for trilaciclib in China.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"751-760"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost comparison of F(ab')₂ and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis. F（ab’）2和fab抗蛇毒血清在美国用于蝮蛇中毒的成本比较：一个真实世界的分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-02-12 DOI: 10.1080/14737167.2025.2462236

Walter Garcia-Ubbelohde, Lia Pizzicato, Keith J Boesen, Swapna Munnangi, Liucheng Shi, Nicholas B Hurst, Mitchell DeKoven

{"title":"Cost comparison of F(ab')2 and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis.","authors":"Walter Garcia-Ubbelohde, Lia Pizzicato, Keith J Boesen, Swapna Munnangi, Liucheng Shi, Nicholas B Hurst, Mitchell DeKoven","doi":"10.1080/14737167.2025.2462236","DOIUrl":"10.1080/14737167.2025.2462236","url":null,"abstract":"Background: This study compared healthcare resource utilization (HCRU) and cost among patients treated for pit viper envenomation with Fab or F(ab')2 antivenom in the United States.Research design and methods: Patients administered Fab or F(ab')2 between January 2019 and September 2022 were identified from IQVIA's New Data Warehouse and placed into two mutually exclusive cohorts. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline differences between cohorts. All-cause HCRU and cost were assessed in the 6-months following antivenom administration (post-index) and compared between IPTW-adjusted cohorts.Results: In total, 242 and 98 patients receiving Fab and F(ab')2 were identified, respectively. Pre-IPTW adjustment, cohorts differed on demographics and select comorbidities (standardized mean difference [SMD] ≥0.10). Post-IPTW, most variables were balanced (SMD < 0.01). Post-index total (Fab: $70,994; F(ab')2: $55,324), medical ($69,162; $52,339), and inpatient costs ($49,466; $29,730) were higher among Fab than F(ab')2 patients (all p < 0.05). After multivariable adjustment, the total (cost ratio [CR]: 0.83; 95% confidence interval [CI]: 0.70-0.98), inpatient (CR: 0.63; 95% CI: 0.51-0.79), and inpatient pharmacy costs (CR: 0.48; 95% CI: 0.33-0.68) were lower in the F(ab')2 than Fab cohort.Conclusions: Patients administered Fab had higher post-index total, inpatient, and inpatient pharmacy costs than patients administered F(ab')2 AV.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"721-728"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China. 中国广泛期小细胞肺癌患者一线化疗中加入tislelizumab的综合经济价值评价

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-06-01 Epub Date: 2025-03-28 DOI: 10.1080/14737167.2025.2483423

Shan Zhao, Shuo Kang

{"title":"Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China.","authors":"Shan Zhao, Shuo Kang","doi":"10.1080/14737167.2025.2483423","DOIUrl":"10.1080/14737167.2025.2483423","url":null,"abstract":"Background: The cost-effectiveness of tislelizumab plus chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC) was uncleared yet. The current analysis aimed to evaluate the cost-effective of adding tislelizumab to the first-line chemotherapy for patients with untreated ES-SCLC from the Chinese health-care system perspective.Research design and methods: A partitioned survival model that simulated 3-week patients transition in 10-year time horizon was established to evaluate the economic value. The clinical benefit and safety data were gathered from the RATIONALE-312 trial, model parameters were gathered from the local charges and previously published studies. Sensitivity analyses and subgroup analyses were conducted to examine the robustness of the model outcomes.Results: Tislelizumab plus chemotherapy could bring additional 0.61 LYs and 0.30 QALYs with the marginal cost of $5,849.40, resulting in the incremental cost-effectiveness ratio (ICER) of $19,592.08 per additional quality-adjusted life-years (QALYs) gained. Sensitivity analyses and subgroup analyses confirmed the robustness of the model results for both intention-to-treat patients and all subgroup patients.Conclusions: Tislelizumab plus chemotherapy could be considered cost-effective first-line therapy for patients with untreated ES-SCLC patients compared with chemotherapy alone from the perspective of Chinese health-care system.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"805-811"},"PeriodicalIF":1.8,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer. FOLFOXIRI +贝伐单抗与mFOLFOX6 +贝伐单抗作为转移性结直肠癌一线治疗的成本-效果分析

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-29 DOI: 10.1080/14737167.2025.2509706

Tong Liu, Yao Yao, Bingjie Liu, Xue Teng, Mei Dong, Xin Zhang

{"title":"Cost-effectiveness analysis of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment of metastatic colorectal cancer.","authors":"Tong Liu, Yao Yao, Bingjie Liu, Xue Teng, Mei Dong, Xin Zhang","doi":"10.1080/14737167.2025.2509706","DOIUrl":"10.1080/14737167.2025.2509706","url":null,"abstract":"Objectives: We first evaluated the cost-effectiveness of the FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab as the first-line treatment of metastatic colorectal cancer from healthcare system perspective.Methods: A partitioned survival model was developed to assess the costs and effects of FOLFOXIRI plus bevacizumab versus mFOLFOX6 plus bevacizumab. Health outcomes were measured in quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). The evaluation of the Chinese healthcare payer perspective was performed across a lifetime horizon, encompassing direct medical expenses.Results: The estimated cost for FOLFOXIRI plus bevacizumab treatment was 9306.364USD, which was higher than 8218.436 USD estimated for mFOLFOX6 plus bevacizumab, leading to an ICER of 1961.857 USD per QALY. One-way sensitivity analysis suggested the body surface area (BSA), the cost of irinotecan, and the cost of fluorouracil had the largest impact on the ICER. The cost-effectiveness acceptability curves showed the probability of FOLFOXIRI plus bevacizumab being cost-effective was100% at a threshold of 12 300 USD per QALY.Conclusion: FOLFOXIRI plus bevacizumab had an economic advantage compared to mFOLFOX6 plus bevacizumab as the first-line treatment of metastatic CRC in China.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis. 在美国，lecanemab对早期阿尔茨海默病医疗保险受益人的预算影响：一个亚组分析。

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-22 DOI: 10.1080/14737167.2025.2507427

Vassiki Sanogo, Reem Dhayan Saud Almutairi, Vakaramoko Diaby

{"title":"Budget impact of lecanemab for medicare beneficiaries with early Alzheimer's disease in the United States: a subgroup analysis.","authors":"Vassiki Sanogo, Reem Dhayan Saud Almutairi, Vakaramoko Diaby","doi":"10.1080/14737167.2025.2507427","DOIUrl":"10.1080/14737167.2025.2507427","url":null,"abstract":"Background: In 2024, Alzheimer's disease affected approximately 6.9 million Americans aged 65 and older. Current therapies include acetylcholinesterase inhibitors, N-methyl-D-aspartate receptor inhibitors, and monoclonal antibodies. With an economic burden surpassing $345 billion, $222 billion borne by Medicare and Medicaid, this study evaluates lecanemab's budgetary impact for early AD, including subgroup analyses by gender and race.Methods: A budget impact model evaluated LECA for early Alzheimer's disease, comparing scenarios with and without the therapy. Inputs included market share, costs, duration, and compliance. Gender and race subgroup analyses, annual costs, PMPM, PTMPM, and sensitivity analysis outcomes were assessed to explore parameter-driven variability comprehensively.Results: Introducing LECA for over 3.5 million eligible early AD patients in the U.S. may generate a three-year budget impact of $4.1 billion for Medicare. Incremental PMPM savings were $1.4, and PTMPM savings reached $24.1. Subgroup analyses revealed no significant gender or racial differences in PMPM and PTMPM, with variability only in overall budget impact. Sensitivity analyses indicate that enhanced healthcare resource utilization, reduced disease severity, and improved cost-efficiency among males contribute to strengthening Medicare's budget sustainability.Conclusions: Utilizing LECA as a treatment for early AD is expected to be cost saving with respect to Medicare budgets in the U.S.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in China. 中国慢性阻塞性肺疾病中重度加重对临床预后和经济负担的影响

IF 1.8 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-05-19 DOI: 10.1080/14737167.2025.2507425

Lei Gan, Xiaoning He, Jing Wu

{"title":"Impact of moderate and severe exacerbations on clinical prognosis and economic burden of chronic obstructive pulmonary disease in China.","authors":"Lei Gan, Xiaoning He, Jing Wu","doi":"10.1080/14737167.2025.2507425","DOIUrl":"10.1080/14737167.2025.2507425","url":null,"abstract":"Objectives: Different severities of exacerbations of chronic obstructive pulmonary disease (AECOPD) will lead to different disease progression and economic burden. This study aimed to evaluate the impact of the severity of AECOPD on disease burden.Methods: Data were from the Tianjin Urban Employee Basic Medical Insurance Database (2016-2020). COPD patients were stratified by severity of AECOPD: (A) no AECOPD, (B) moderate AECOPD only; and (C) ≥1 severe AECOPD. Key outcomes included rate of AECOPD, mortality, COPD-related cost. Sensitivity analysis of reducing the impact of COVID-19 in outcomes was conducted.Results: 6738 patients were identified, with 22.5% for Group A, 41.1% for Group B and 36.4% for Group C. During 1st follow-up year, Group C experienced an average of 1.43 severe AECOPD, leading to a notably increased all-cause mortality (Group C vs A-B: 17.7% vs. 2.6-3.4%, p < 0.001), highest COPD-related costs (CNY 30,245 vs 1,700-6,923). In the second year, patients in Group C still had a highest rate of severe AECOPD (0.44 vs 0.08-0.11 vs, p < 0.001), as well as increased all-cause mortality.Conclusion: Severe AECOPD significantly increased mortality rates and economic burden in the current and subsequent year. This underscored the imperative need to enhance severe AECOPD management.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0